康泰生物(300601.SZ):控股股東及其一致行動人持股比例降至49.85%
格隆匯 2 月 4日丨康泰生物(300601.SZ)公佈,截至2021年2月3日,因2019年股票期權激勵計劃首次授予股票期權第一個行權期行權增加公司股本1315.83萬股,公司總股本增加至6.86億股。公司總股本增加,導致控股股東及其一致行動人持股比例被動稀釋;另外,控股股東的一致行動人YUAN LIPING按照預先披露的減持計劃通過大宗交易、集中競價方式減持股份481.16萬股。上述原因導致其持有公司股份的比例變動超過1%。此次變動後,控股股東及其一致行動人持股比例由51.14%降至49.85%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.